Zurcher Kantonalbank Zurich Cantonalbank Purchases 195 Shares of Penumbra, Inc. (NYSE:PEN)
Zurcher Kantonalbank Zurich Cantonalbank grew its position in Penumbra, Inc. (NYSE:PEN) by 5.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,875 shares of the company’s stock after acquiring an additional 195 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Penumbra were worth $753,000 as of its most recent SEC filing.
Several other hedge funds have also recently made changes to their positions in the business. Driehaus Capital Management LLC lifted its position in shares of Penumbra by 1.6% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,822 shares of the company’s stock worth $505,000 after buying an additional 44 shares during the period. Crossmark Global Holdings Inc. increased its holdings in Penumbra by 1.5% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 4,632 shares of the company’s stock valued at $900,000 after purchasing an additional 70 shares in the last quarter. Comerica Bank increased its holdings in Penumbra by 0.4% during the 3rd quarter. Comerica Bank now owns 20,298 shares of the company’s stock valued at $4,791,000 after purchasing an additional 87 shares in the last quarter. First Bank & Trust increased its position in Penumbra by 7.9% in the third quarter. First Bank & Trust now owns 1,330 shares of the company’s stock worth $258,000 after purchasing an additional 97 shares during the period. Finally, Louisiana State Employees Retirement System lifted its position in Penumbra by 1.2% during the 3rd quarter. Louisiana State Employees Retirement System now owns 8,400 shares of the company’s stock valued at $1,633,000 after purchasing an additional 100 shares during the period. Institutional investors own 84.02% of the company’s stock.
In other Penumbra news, CEO Adam Elsesser sold 8,000 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $200.73, for a total transaction of $1,605,840.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider James Robert Pray sold 5,000 shares of the firm’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $212.74, for a total value of $1,063,700.00. Following the sale, the insider now directly owns 1,578 shares of the company’s stock, valued at approximately $335,703.72. The disclosure for this sale can be found here. In the last three months, insiders sold 37,591 shares of company stock valued at $8,661,048. 8.90% of the stock is currently owned by insiders.
NYSE PEN opened at $259.15 on Friday. The company has a market cap of $9.41 billion, a PE ratio of 893.65 and a beta of 0.67. The company has a current ratio of 7.42, a quick ratio of 5.06 and a debt-to-equity ratio of 0.04. Penumbra, Inc. has a 12 month low of $121.80 and a 12 month high of $277.00. The stock has a 50 day moving average of $232.37 and a 200-day moving average of $204.59.
Penumbra (NYSE:PEN) last released its quarterly earnings data on Wednesday, October 28th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.13) by $0.19. The company had revenue of $151.08 million during the quarter, compared to the consensus estimate of $125.60 million. Penumbra had a return on equity of 1.25% and a net margin of 2.02%. As a group, sell-side analysts predict that Penumbra, Inc. will post -0.24 EPS for the current fiscal year.
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands.
Recommended Story: What are Bollinger Bands?
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.